Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy-MedSci.cn

Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy

Hepner, A; Carlino, MS; Johnson, DB; Gerard, CL; Lo, S; Pallan, L; Silva, ID; Michielin, OA; Long, GV; Menzies, AM

ANNALS OF ONCOLOGY, 2019; 30 ():

科室
- - 订阅+
  - 更多科室
工具
服务